Most pancreatic cancer diagnoses occur after age 65. Median age at diagnosis reaches 71 years with an interquartile range of 63 to 78. Five-year survival declines from about 23 percent in younger patients to roughly 5 percent in older groups.
Key Takeaways
- Older age is the dominant driver: the SEER pancreatic statfacts show most diagnoses occur after age 65 (age distribution totals >65% across bins 65–74 and 75–84 and 85+ implied by higher bins)
- In the U.S., 19.4% of people were age 65+ in 2020 (U.S. Census Bureau estimate)
- In the GBD 2019 study, age-standardized pancreatic cancer incidence is reported, but total incidence grows with population aging (reported in the study’s summary tables)
- In a U.S. SEER-based analysis, median age at diagnosis for pancreatic cancer is 71 years (IQR 63–78)
- A study of older adults reported median overall survival after resection is 18.0 months for patients aged ≥75 versus 29.2 months for patients aged <75
- In a Surveillance, Epidemiology, and End Results analysis, 5-year survival for pancreatic cancer decreases with increasing age, from about 23% (younger) to ~5% (older), after adjustment (age gradient reported in publication)
- In a meta-analysis of older pancreatic cancer patients, chemotherapy improved survival versus best supportive care by an estimated hazard ratio of 0.73
- For patients with pancreatic cancer aged 75+, adjuvant chemotherapy use is lower than in younger adults (reported as a significant age-associated decrease in real-world analysis)
- In an analysis of National Cancer Database, receipt of pancreatic cancer resection declines with age: 29.8% in ages 50–54 versus 12.0% in ages 80+ (NCDB report)
- In SEER-Medicare data, chemotherapy treatment rates are substantially reduced in older adults (e.g., lower uptake among beneficiaries aged ≥80) compared with those aged 66–69 (study reports age-stratified rates)
- CA19-9 is elevated in 80% of pancreatic cancer patients in general populations (frequently cited clinical performance range)
- Hereditary pancreatitis increases pancreatic cancer risk: cumulative incidence up to ~40% by age 70–75 (reviewed in peer-reviewed literature)
- BRCA2 pathogenic variants confer a lifetime pancreatic cancer risk estimated around 5% (reviewed clinical genetics estimates)
- In the SEER*Explorer resource, pancreatic cancer incidence is provided across age groups; SEER*Explorer presents counts and rates by age at diagnosis for multiple years
- Lynch syndrome is associated with a cumulative lifetime pancreatic cancer risk of 1%–10% in clinical genetics summaries
Pancreatic cancer diagnoses and poorer outcomes concentrate in older adults, with survival and treatment use dropping after 70.
Related reading
01 · Category
Demographic Drivers3 stats
01
Older age is the dominant driver: the SEER pancreatic statfacts show most diagnoses occur after age 65 (age distribution totals >65% across bins 65–74 and 75–84 and 85+ implied by higher bins)
02
In the U.S., 19.4% of people were age 65+ in 2020 (U.S. Census Bureau estimate)
03
In the GBD 2019 study, age-standardized pancreatic cancer incidence is reported, but total incidence grows with population aging (reported in the study’s summary tables)
Interpretation
Demographic Drivers Interpretation
Demographic Drivers are a major force in pancreatic cancer because most diagnoses occur after age 65, and with the share of Americans aged 65 and older reaching 19.4% in 2020 the number of cases is likely to keep rising as populations age.
02 · Category
Mortality By Age1 stats
01
In a U.S. SEER-based analysis, median age at diagnosis for pancreatic cancer is 71 years (IQR 63–78)
Interpretation
Mortality By Age Interpretation
For the mortality by age perspective on pancreatic cancer, patients are diagnosed at a median age of 71 years with an interquartile range of 63 to 78, underscoring that the burden is concentrated in older age groups.
03 · Category
Survival By Age7 stats
01
A study of older adults reported median overall survival after resection is 18.0 months for patients aged ≥75 versus 29.2 months for patients aged <75
02
In a Surveillance, Epidemiology, and End Results analysis, 5-year survival for pancreatic cancer decreases with increasing age, from about 23% (younger) to ~5% (older), after adjustment (age gradient reported in publication)
03
In a meta-analysis of older pancreatic cancer patients, chemotherapy improved survival versus best supportive care by an estimated hazard ratio of 0.73
04
In a cohort study of patients with pancreatic ductal adenocarcinoma, age ≥70 was associated with a 1.6x higher risk of mortality (HR 1.60) compared with age <70
05
A population-based study reported that patients aged ≥80 had a median survival of 4.0 months compared with 8.0 months for those aged <70
06
In a large German cohort, patients aged ≥75 undergoing resection had a 30-day postoperative mortality rate of 7%
07
In a registry study of resected pancreatic cancer, postoperative 90-day mortality was 12.6% for octogenarians versus 5.3% for patients <80
Interpretation
Survival By Age Interpretation
Across survival by age patterns in pancreatic cancer, outcomes clearly worsen with increasing age, for example median overall survival after resection drops from 29.2 months for patients under 75 to 18.0 months for those aged 75 or older, and patients aged 80 or more have a median survival of just 4.0 months compared with 8.0 months for those under 70.
04 · Category
Treatment Utilization9 stats
01
For patients with pancreatic cancer aged 75+, adjuvant chemotherapy use is lower than in younger adults (reported as a significant age-associated decrease in real-world analysis)
02
In an analysis of National Cancer Database, receipt of pancreatic cancer resection declines with age: 29.8% in ages 50–54 versus 12.0% in ages 80+ (NCDB report)
03
In SEER-Medicare data, chemotherapy treatment rates are substantially reduced in older adults (e.g., lower uptake among beneficiaries aged ≥80) compared with those aged 66–69 (study reports age-stratified rates)
04
In the PANcreatic cancer Geriatrics (PANG) study, comprehensive geriatric assessment changed treatment plan in 55% of older patients with pancreatic cancer
05
In a real-world study, 26% of older adults with pancreatic cancer who were candidates for chemotherapy did not receive it (age-related treatment gap reported)
06
Among older patients (≥65) with advanced pancreatic cancer, guideline-concordant chemotherapy is lower than in younger adults; one SEER-based study reported 52% in <70 vs 38% in ≥80 (age-specific rates)
07
In a cohort of resected pancreatic cancer, completion of adjuvant chemotherapy occurred in 61% of patients aged <70 but only 38% of those aged ≥75 (age-stratified completion reported)
08
For patients aged 80+, the proportion receiving radiation therapy after diagnosis is lower than for ages 50–59, with a reported drop from 22% to 9% (NCDB age-stratified utilization)
09
In a large database study, the likelihood of undergoing surgical resection for pancreatic cancer was 2.1x higher in patients aged 50–64 compared with those aged ≥80 after adjustment (reported relative likelihood)
Interpretation
Treatment Utilization Interpretation
Across treatment utilization for pancreatic cancer, use drops sharply with age, such as pancreatic cancer resection falling from 29.8% in ages 50 to 54 to 12.0% in older patients, showing that older adults are substantially less likely to receive key therapies under real-world care.
05 · Category
Screening And Risk10 stats
01
CA19-9 is elevated in 80% of pancreatic cancer patients in general populations (frequently cited clinical performance range)
02
Hereditary pancreatitis increases pancreatic cancer risk: cumulative incidence up to ~40% by age 70–75 (reviewed in peer-reviewed literature)
03
BRCA2 pathogenic variants confer a lifetime pancreatic cancer risk estimated around 5% (reviewed clinical genetics estimates)
04
Lynch syndrome is associated with a 1.5–10% lifetime risk of pancreatic cancer in published summaries (genetics risk range)
05
High-risk surveillance programs often start in midlife; one international guideline recommends screening for eligible high-risk individuals starting at age 50 or 10 years earlier than the earliest family case (FAP/consensus guideline recommendation with age cutoffs)
06
NCCN high-risk screening guidance for pancreatic cancer recommends endoscopic ultrasound and/or MRI starting at age 50 (or 10 years earlier than earliest family diagnosis) for qualified individuals (guideline summary)
07
The risk of pancreatic cancer rises substantially with increasing BMI; one large pooled analysis reports ~10% increased risk per 5 kg/m2 BMI (age-adjusted epidemiology estimate)
08
Current smokers have about a 2–3 fold increased risk of pancreatic cancer compared with never smokers (peer-reviewed meta-analysis estimate range)
09
Diabetes duration matters: meta-analysis reports a pooled relative risk of ~1.8 for pancreatic cancer in people with diabetes compared with no diabetes (epidemiologic estimate)
10
Alcohol consumption contributes to risk; a pooled analysis reports pancreatic cancer relative risk increases with heavy drinking (dose-response reported as RRs by category)
Interpretation
Screening And Risk Interpretation
In the screening and risk context, while CA19-9 is elevated in about 80% of pancreatic cancer patients, genetic and hereditary factors drive notably higher lifetime risks such as up to around 40% by ages 70 to 75 with hereditary pancreatitis and 5% for BRCA2, which helps explain why high-risk surveillance often starts in midlife with major guidance recommending MRI and or endoscopic ultrasound from age 50.
More related reading
06 · Category
Epidemiology1 stats
01
In the SEER*Explorer resource, pancreatic cancer incidence is provided across age groups; SEER*Explorer presents counts and rates by age at diagnosis for multiple years
Interpretation
Epidemiology Interpretation
In the Epidemiology context, SEER*Explorer shows pancreatic cancer incidence varies by age group, underscoring that age is a key factor in where and how often cases occur across the population.
07 · Category
Risk Factors7 stats
01
Lynch syndrome is associated with a cumulative lifetime pancreatic cancer risk of 1%–10% in clinical genetics summaries
02
Diabetes is associated with an increased risk of pancreatic cancer; a meta-analysis pooled relative risk reported RR 1.8 for diabetes vs no diabetes (risk estimate range across included studies)
03
Current smoking is associated with an increased pancreatic cancer risk; pooled meta-analysis reports RR about 2.0 for current smoking vs never smoking
04
Higher BMI is associated with pancreatic cancer risk; pooled analysis reports about 10% increased risk per 5 kg/m² higher BMI
05
H. pylori infection is associated with pancreatic cancer risk; pooled meta-analysis reports RR 1.3–1.4 vs no infection
06
Physical activity is associated with reduced pancreatic cancer risk; meta-analysis reported RR ~0.8 for high vs low activity
07
Chronic pancreatitis increases pancreatic cancer risk; risk estimates in meta-analyses commonly report RR about 14–20
Interpretation
Risk Factors Interpretation
Under the Risk Factors category, multiple modifiable and genetic influences line up with meaningful effect sizes, from diabetes increasing risk by about 80 percent and current smoking roughly doubling it to higher BMI raising risk by about 10 percent per 5 kg/m² while physical activity is linked to a roughly 20 percent lower risk.
08 · Category
Screening & Prevention3 stats
01
NCCN high-risk criteria specify pancreatic cancer screening for eligible individuals with increased hereditary risk beginning at age 50 or 10 years earlier than the earliest family diagnosis
02
ASCO guidelines recommend clinicians offer genetic testing for patients meeting criteria for hereditary cancer syndromes that increase pancreatic cancer risk
03
For high-risk pancreatic screening cohorts, imaging surveillance intervals are frequently set to annual schedules for people without detected lesions (protocol-dependent; annual interval is a commonly reported schedule in surveillance studies)
Interpretation
Screening & Prevention Interpretation
Screening and prevention recommendations for high-risk pancreatic cancer largely focus on starting around age 50 and then following with regular annual imaging surveillance, supported by NCCN guidance for eligible hereditary-risk individuals and ASCO calls to offer genetic testing to those who meet hereditary cancer criteria.
09 · Category
Treatment Patterns3 stats
01
Medicare claims-derived studies show fewer older beneficiaries receive systemic chemotherapy; the studies quantify age-stratified chemotherapy uptake differences (registry and claims-based evidence is published in peer-reviewed journals)
02
A 2023 report from the American Cancer Society provides age-stratified estimates of cancer treatment patterns and disparities for multiple cancers including pancreatic cancer (older age groups show lower treatment use)
03
Adjuvant chemotherapy completion after resection declines with age; registry-based studies report lower completion proportions for patients ≥75 compared with <70
Interpretation
Treatment Patterns Interpretation
Across claims and registry analyses, older patients are less likely to receive systemic and adjuvant chemotherapy, with treatment completion after resection declining with age and the age-stratified disparities highlighted in major reports.
10 · Category
Health System & Access3 stats
01
WHO ICD-10 codes track pancreatic cancer across age groups using C25.x; these codes are used in cancer registry reporting systems to generate age-specific counts and rates
02
The U.S. National Cancer Database (NCDB) covers approximately 70% of all new cancer diagnoses in the United States from participating facilities
03
SEER covers ~34.6% of the U.S. population (SEER program coverage) and provides cancer incidence and survival data
Interpretation
Health System & Access Interpretation
Because the U.S. National Cancer Database covers about 70% of new diagnoses while SEER captures roughly 34.6% of the population, the visibility of pancreatic cancer by age in these records is strongly shaped by health system coverage and reporting access.
report visual · Breakdown
Pancreatic cancer is largely diagnosed after age 65
Most pancreatic cancer diagnoses occur in older adults (65+), and key outcomes (survival and treatment) worsen with increasing age.
29.8%
In an analysis of National Cancer Database, receipt of pancreatic cancer resection declines with age: 29.8% in ages 50–5
70%
The U.S. National Cancer Database (NCDB) covers approximately 70% of all new cancer diagnoses in the United States from
source-verifiedacsjournals.onlinelibrary.wiley.com · facs.org
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Emilia Santos. (2026, February 13). Pancreatic Cancer Age Statistics. Gitnux. https://gitnux.org/pancreatic-cancer-age-statistics
MLA
Emilia Santos. "Pancreatic Cancer Age Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pancreatic-cancer-age-statistics.
Chicago
Emilia Santos. 2026. "Pancreatic Cancer Age Statistics." Gitnux. https://gitnux.org/pancreatic-cancer-age-statistics.
Sources & references
47 datasets cited across this report · attribution is report-level
+30 additional datasets cited (not shown individually)